The INHERIT trial is testing intranasal heparin to treat early COVID-19 infection.
Intranasal heparin may be able to treat people with early COVID-19 infection and prevent infection amongst their close household contacts, helping to reduce the spread of the virus. This trial has public health significance and general practice outreach can make an important contribution.
The Department of General Practice and Primary Care, University of Melbourne through the Victorian Research and Education Network (VicREN) works closely with GPs and practice staff to ensure that general practice has equitable access to relevant trials as part of routine care provided in the general practice setting or as an additional treatment option to usual care.
Is your practice located across the northern regions of Melbourne?
Depending on your practice capacity, our VicREN team can work with you to help spread the word about this important study and alert interested patients with symptoms to consider taking part.
Further information:
E: vicrenres-enquiries@unimelb.edu.au.
W: www.nh.org.au/inherit-the-intranasal-heparin-trial/
Disclaimer: This article was provided by Maria Stambas, University of Melbourne. While every effort has been made to ensure the information is accurate, North Western Melbourne Primary Health Network does not warrant or represent the accuracy, currency and completeness of any information or material included within.
